常任理事

Medicine & Life Sciences

1. Rheumatoid Arthritis 100%
2. Esophageal Neoplasms 81%
3. Pemphigus 77%
4. Esophagectomy 61%
5. Japan 55%
6. Stomach Neoplasms 52%
7. Neoplasms 48%
8. Desmoglein 3 47%
9. Esophageal Squamous Cell Carcinoma 45%
10. Methotrexate 40%
11. Neoplasm Metastasis 39%
12. Safety 37%
13. Therapeutics 36%
14. Lymph Nodes 29%
15. Autoantibodies 28%
16. Sentinel Lymph Node 28%
17. Recurrence 27%
18. Survival 26%
19. Colorectal Neoplasms 25%
20. Drug Therapy 25%
21. Liver Transplantation 24%
22. Immunoglobulin G 24%
23. tocilizumab 24%
24. Spine 23%
25. Desmoglein 1 23%
26. Chemoradiotherapy 22%
27. Skin 22%
28. Joints 21%
29. Serum 21%
30. Liver 20%
31. Living Donors 20%
32. Laparoscopy 20%
33. Thorax 19%
34. Cisplatin 18%
35. Fluorouracil 18%
36. Desmogleins 18%
37. Antibodies 18%
38. Breast Neoplasms 18%
39. Transplants 18%
40. Gastrectomy 18%
41. Systemic Lupus Erythematosus 17%
42. Adalimumab 17%
43. Stomach 17%
44. Lymph Node Excision 17%
45. Placebos 16%
46. baricitinib 16%
47. Antirheumatic Agents 16%
48. Pancreatic Neoplasms 16%
49. Spinal Cord 15%
50. Abatacept 15%
51. Incidence 14%
52. Ossification of Posterior Longitudinal Ligament 14%
53. Bullous Pemphigoid 14%
54. Postoperative Complications 14%
55. Gastrointestinal Neoplasms 14%
56. Immunoglobulin G4-Related Disease 13%
57. Infliximab 13%
58. Carcinoma 13%
59. Knee 13%
60. Biomarkers 13%
61. Laminoplasty 13%
62. Retrospective Studies 13%
63. Adenocarcinoma 13%
64. Genes 13%
65. Blister 13%
66. Multicenter Studies 12%
67. Spinal Cord Injuries 12%
68. Spinal Cord Diseases 12%
69. Bone and Bones 12%
70. Scoliosis 12%
71. Esophagus 12%
72. Cohort Studies 12%
73. Magnetic Resonance Imaging 11%
74. T-Lymphocytes 11%
75. Autoimmune Diseases 11%
76. Keratinocytes 11%
77. Atopic Dermatitis 11%
78. Prospective Studies 11%
79. Systematic Reviews 10%
80. filaggrin 10%
81. Surgical Wound Infection 10%
82. Transplantation 10%
83. Rheumatology 10%
84. Mutation 10%
85. B-Lymphocytes 10%
86. Osteoclasts 10%
87. Hepatocellular Carcinoma 10%
88. Anti-Idiotypic Antibodies 10%
89. C-Reactive Protein 10%
90. Interleukin-6 10%
91. Squamous Cell Carcinoma 10%
92. Stem Cells 10%
93. Phenotype 10%
94. peficitinib 9%
95. Tomography 9%
96. Pneumonia 9%
97. Infections 9%
98. Lung 9%
99. Wounds and Injuries 9%
100. Pancreaticoduodenectomy 9%